LUCIUS 卢修斯 莫博替尼 Mobocertinib 非小细胞肺癌 (EGFR20突变)

莫博替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Mobocertinib

老挝国家食药监局批准上市
老挝国家药检所检测认证
非小细胞肺癌

Composition:

Each LuciMob capsule contains: 48.06m

LUCIUS

Mobocertinib succinate equivalent to

HARMACEUTI

(EGFR20突变)

LuciMob is a kinase inhibitor indicated for the
treatment of adult patients with locally
advanced or metastatic non-small cell lu

LuciMob

C) with epidermal growto Tacior
receptor (ElFR)exon 20 insertion mutations,
detacted hu an FDA.anproved test
detected by an FDA-approved Test, whose
uiscase has progressed on or after platinum
based chemotheriny

40mg

The recom monds

ewoctided dosage of LuciMoo is 16U mg
dally until discase progression or

Mobocertinib Capsules

FDA批准

ceysuie snould be swallowed whole & not

120 Capsules

Sorage: in a dry place and store at 20℃ to 25℃
Warning:
Keep medicine out of the reach of Children. Do
not administered LuciMob in Pregnancy and
Lactation noa
Lactation patient treatment.
PLEASESEE PACKAGE INSER
Preonancy ank
Manufactured and Marketed by
LUCIUS

权威认证

Thongmang village, Xaythany district
eitlane Capital, Laos
Warning: To be sold by retail on prescriptio
of a Kegistered oncologist only, and as directee
by the physician.

Rx Only

口碑质量

适应症:

适用于治疗具有表皮生长因子受体(EGFR)外显子20插入突变的局部晚期或转移性非小细胞肺癌(NSCLC)的成
年患者,其疾病在铂的化疗期间或之后进展。

推荐剂量:
每日口服一次,每次160mg,随或不随食物